Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Byrne

Showing results (41-50 of 458) with videos related to

Pageof 46
Sort By:
Gut|August 9, 2022
Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?Christopher D Byrne, Giovanni Targher
World Journal of Gastroenterology|September 7, 2010
Obstructive sleep apnea syndrome and fatty liver: association or causal link?Mohamed-H Ahmed, Christopher-D Byrne
BMJ (Clinical Research Ed.)|March 13, 2010
Body fat and increased risk of cirrhosisChristopher D Byrne, S H Wild
Journal of Hepatology|February 12, 2025
Metabolic dysfunction-associated steatotic liver disease a multisystem disease: Assessing the cost effectiveness of pharmacotherapiesChristopher D Byrne, Gregory J Dore
The Journal of Nutrition|August 24, 2018
Nutritional Targeting of Cancer Cell Metabolism in ObesityJaswinder K Sethi, Christopher D Byrne
BMJ (Clinical Research Ed.)|May 6, 2016
Body mass index and mortality: understanding the patterns and paradoxesSarah H Wild, Christopher D Byrne
Evidence-Based Medicine|February 1, 2008
Review: thiazolidinediones increase risk of heart failure in type 2 diabetesChristopher D Byrne, Sarah H Wild
Diabetes, Obesity & Metabolism|June 20, 2008
Current treatment of non-alcoholic fatty liver diseaseMohamed H Ahmed, Christopher D Byrne
Nutrition Research Reviews|December 17, 2008
Evidence for fetal programming of obesity with a focus on putative mechanismsSarah H Wild, Christopher D Byrne
Drug Discovery Today|September 11, 2007
Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)Mohamed H Ahmed, Christopher D Byrne
Pageof 46

Showing results (41-50 of 458) with videos related to

Sort By:
Pageof 46
Gut|August 9, 2022
Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?Christopher D Byrne, Giovanni Targher
World Journal of Gastroenterology|September 7, 2010
Obstructive sleep apnea syndrome and fatty liver: association or causal link?Mohamed-H Ahmed, Christopher-D Byrne
BMJ (Clinical Research Ed.)|March 13, 2010
Body fat and increased risk of cirrhosisChristopher D Byrne, S H Wild
Journal of Hepatology|February 12, 2025
Metabolic dysfunction-associated steatotic liver disease a multisystem disease: Assessing the cost effectiveness of pharmacotherapiesChristopher D Byrne, Gregory J Dore
The Journal of Nutrition|August 24, 2018
Nutritional Targeting of Cancer Cell Metabolism in ObesityJaswinder K Sethi, Christopher D Byrne
BMJ (Clinical Research Ed.)|May 6, 2016
Body mass index and mortality: understanding the patterns and paradoxesSarah H Wild, Christopher D Byrne
Evidence-Based Medicine|February 1, 2008
Review: thiazolidinediones increase risk of heart failure in type 2 diabetesChristopher D Byrne, Sarah H Wild
Diabetes, Obesity & Metabolism|June 20, 2008
Current treatment of non-alcoholic fatty liver diseaseMohamed H Ahmed, Christopher D Byrne
Nutrition Research Reviews|December 17, 2008
Evidence for fetal programming of obesity with a focus on putative mechanismsSarah H Wild, Christopher D Byrne
Drug Discovery Today|September 11, 2007
Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)Mohamed H Ahmed, Christopher D Byrne
Pageof 46